Novartis Access Impact Evaluation Progress Update

This technical report outlines the ongoing evaluation of Novartis Access in Kenya, conducted by Boston University. The study, led by Peter C. Rockers, aims to assess the program's impact on access to non-communicable disease (NCD) medicines. Initial findings reveal significant geographic disparities in diagnosed hypertension and diabetes, particularly in rural areas where access to diagnostic services is limited. The report indicates a wealth gradient affecting access to medicines, with poorer patients facing higher costs and limited availability. The evaluation suggests that Novartis Access could enhance equity by targeting underserved communities. Midline results indicate potential adjustments to the program, including the distribution of medicines through private sector outlets and tailoring strategies to local healthcare systems. The report emphasizes the importance of a mobile phone-based data collection method developed during the study, which could facilitate similar evaluations in other countries. Overall, the findings aim to contribute to the global discourse on improving access to medicines.